格隆汇9月5日丨步长制药(603858.SH)公布，公司于2025年9月4日召开第五届董事会第三十一次会议，审议通过了《关于拟注销长沙众测生物科技有限公司的议案》《关于拟注销湖南众测生 为进一步优化资源配置，降低管理成本，公司拟注销控股子公司长沙众测生物、湖南众测生物，本次注销完成后，不会对公司合并财务报表产生实质性影响，不会对公司整体业务发展和盈利水平 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 担保对象及基本情况 ■ ● 累计担保情况 ■ 山东步长制药股份有限公司（以下简称"公司"）于2025年9月1日与北京银行股份有限公司西安分行（以 下简称"北京银行西安分行"）签订《最高额保证合同》，为公司全资子公司杨凌步长制药有限公司（以 下简称"杨凌步长"）与北京银行西安分行签订的《综合授信合同》提供10,000万元连带责任保证。 （二）内部决策程序 公司于2025年4月25日召开第五届董事会第二十次（年度）会议，于2025年6月26日召开2024年年度股东 会，审议通过了《关于审议公司及控股子公司2025年度预计新增融资额度及担保额度的议案》，同意 2025年度公司及控股子公司向金融机构申请授信总额不超过人民币69.2亿元的综合融资额度。上述融资 事项如需采用保证或抵押等担保方式，担保额度不超过69.2亿元人民币，其中，对本公司新增担保额度 为260,000.00万元人民币，对资产负债率为70%以上的控股子公司新增担保额度为362,000.00万元人民 币 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-163 山东步长制药股份有限公司 关于为公司全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 254,030.79 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 24.86 | | 特别风险提示（如有请勾选） | □对外担保总额（含本次）超过上市公司最 | | | 近一期经审计净资产 50% | | | □对外担保总额（含本次）超过上市公司最 | | | 近一期经审计净资产 100% | | | □对合并报表外单位担保总额（含本次）达 | | | 到或超过最近一期经审计净资产 30% | | | ☑本次对资产负债率超过 70%的单位提供担 | | 保 | | 一、担保情况概述 （一）担保的基本情况 山东步长制药股份有限公司（以下简称"公司"）于 2 ...

国海证券研报指出，步长制药2025年上半年归母净利润6.28亿元（yoy+171.24%），扣非归母净利润6.19亿元（yoy+180.04%）；Q2归母净利润3.20亿元（yoy+172.94%），上半年收入 ...

| | | | 单位:元 币种:人民币 | | --- | --- | --- | --- | | 主要会计数据 | 本报告期 (1-6月) | 上年同期 | 本报告期比上年同 期增减(%) | | 营业收入 | 5,663,836,253.89 | 5,431,672,307.69 | 4.27 | | 利润总额 | 749,591,545.75 | 403,972,812.43 | 85.55 | | 归属于上市公司股东的净利润 | 627,701,257.33 | 231,416,651.70 | 171.24 | | 归属于上市公司股东的扣除非经常 性损益的净利润 | 618,837,568.16 | 220,981,834.00 | 180.04 | | 经营活动产生的现金流量净额 | 958,968,358.71 | 497,200,080.84 | 92.87 | 上半年，步长制药研发费用为0.84亿元，同比下降31.00%；销售费用为22.39亿元，同比增长 8.26%。 中国经济网北京9月2日讯 步长制药(603858.SH)近日披露的2025年半年度报告显示，公司上半年实 现营业收入56. ...

Core Points - The National Administration of Traditional Chinese Medicine has approved the establishment of the "National Old Medicine Worker Inheritance Studio," a collaboration between Shaanxi International Business College and Shaanxi Buchang Pharmaceutical Co., Ltd. [1] - Professor Liu Feng, the General Manager of Buchang Pharmaceutical's Technology Management Center and Dean of the College of Traditional Chinese Medicine at the school, has been awarded the title of "National Old Medicine Worker" [1] - This project represents a significant breakthrough for the school in building national-level scientific and educational platforms and is a result of the implementation of the "Three Combinations and Five Empowerments" talent cultivation philosophy [1][32] Group 1 - The studio aims to protect and inherit the unique skills of old medicine workers and explore effective paths for the transmission and promotion of traditional Chinese medicine techniques [28] - The project focuses on integrating resources from Buchang Pharmaceutical, including medicinal herb planting bases and research platforms, to create a comprehensive practical training base for the inheritance and talent cultivation of traditional Chinese medicine [4] - The studio will establish a collaborative innovation platform among old medicine workers, universities, and enterprises to promote the full-chain transformation from academic research to industrial application [29][21] Group 2 - The talent cultivation model will be based on a three-in-one approach of apprenticeship education, academic discussion, and skills training, aiming to develop new talents in traditional Chinese medicine who are both knowledgeable and skilled [33][29] - The studio will continue to deepen the integration of industry and education, creating a collaborative ecosystem that connects enterprise needs with educational resources [21] - The successful approval of the studio is a vivid practice of implementing national strategies for the revitalization of traditional Chinese medicine and enhancing the development of the regional industry [32][41]

Core Viewpoint - The company has completed the registration of changes in its business license following the reduction of registered capital through the cancellation of repurchased shares [1][2][3] Group 1: Share Repurchase and Capital Reduction - The company held board meetings on April 25, 2025, and May 26, 2025, to approve the change of purpose for repurchased shares totaling 44,853,573 shares and 6,620,630 shares, respectively, to "reduce registered capital" [1][2] - The company completed the cancellation of repurchased shares on August 12, 2025, as per the announcements made on the Shanghai Stock Exchange [2] Group 2: Business Registration Changes - The company has successfully completed the business registration change and received a new business license from the Heze Market Supervision Administration [3] - The updated registered capital is RMB 1,054,484,432 [3] - The company operates in the production of various pharmaceutical forms, including tablets, hard capsules, granules, and oral liquids [3]

上述事项已经公司 2024 年年度股东会审议通过，具体内容详见公司 2025 年 6 月 27 日披露于上海证券交易所网站（www.sse.com.cn）的《2024 年年度股 东会决议公告》（公告编号：2025-124）。 公司已于 2025 年 8 月 12 日办理完毕回购股份的注销事宜，具体内容详见公 司于 2025 年 8 月 12 日披露于上海证券交易所网站（www.sse.com.cn）的《关于 注销回购股份的实施公告》（公告编号：2025-145）。 公司现已完成工商变更登记手续，并取得了菏泽市市场监督管理局换发的营 业执照，变更后的相关信息如下： 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开 第五届董事会第二十次（年度）会议、第五届监事会第五次（年度）会议，审议 通过了《关于变更回购股份用途并注销暨减少注册资本的议案》，公司拟将存放 于公司回购专用证券账户的 44,853,573 股股份用途变更为"减少公司注册资 本"。具 ...

Core Viewpoint - The trend of mergers and acquisitions (M&A) focusing on core technologies is increasing, driven by companies' responses to innovation-driven development strategies and the need for industry structure optimization and upgrading [2][3]. Group 1: M&A Activity and Trends - Hunan Nanxin Pharmaceutical Co., Ltd. plans to acquire assets and intellectual property rights related to "multiple trace element injection solutions" for no more than 480 million yuan [1]. - There have been 21 M&A projects involving core technologies this year, with a total transaction value of 2.569 billion yuan, highlighting a significant increase in asset-oriented transactions [1][3]. - The number of M&A projects involving core technologies has risen by 50% compared to the same period last year, with 14 projects reported last year [3]. Group 2: Strategic Importance of Core Technologies - Companies are shifting their focus from "buying scale" to "grabbing technology," as mastering core technologies becomes essential for overcoming growth bottlenecks and building differentiated competitive advantages [5]. - Intellectual property (IP) such as patents, trademarks, and copyrights is increasingly recognized as a crucial intangible asset that constitutes core competitiveness and market barriers for companies [5]. Group 3: Sector-Specific Insights - The pharmaceutical manufacturing sector is particularly active in core technology M&A, with 6 out of 21 projects occurring in this field, accounting for nearly 30% of the total [3]. - The semiconductor and biomedicine sectors are highlighted as "bottleneck" areas that require M&A for technological breakthroughs, especially in the context of global industrial chain restructuring [4][6]. Group 4: Future Outlook - The logic of core technology M&A is expected to deepen and expand over the next three to five years, with companies prioritizing technology exclusivity over short-term scale expansion [7]. - This trend is anticipated to extend into more niche areas such as materials, high-end equipment, and software algorithms, driving the overall upgrade of high-tech industries [7].

证券之星价投圈财报分析工具显示： 业务评价：去年的净利率为-6.38%，算上全部成本后，公司产品或服务的附加值不高。从历史年报数据 统计来看，公司上市以来中位数ROIC为12.62%，投资回报也较好，其中最惨年份2022年的ROIC 为-8.87%，投资回报极差。公司历史上的财报相对一般（注：公司上市时间不满10年，上市时间越长财 务均分参考意义越大。），公司上市来已有年报8份，亏损年份2次，显示生意模式比较脆弱。 商业模式：公司业绩主要依靠营销驱动。需要仔细研究这类驱动力背后的实际情况。 据证券之星公开数据整理，近期步长制药（603858）发布2025年中报。截至本报告期末，公司营业总收 入56.64亿元，同比上升4.27%，归母净利润6.28亿元，同比上升171.24%。按单季度数据看，第二季度 营业总收入28.79亿元，同比上升3.14%，第二季度归母净利润3.2亿元，同比上升172.94%。本报告期步 长制药盈利能力上升，毛利率同比增幅9.42%，净利率同比增幅212.49%。 财报体检工具显示： 本次财报公布的各项数据指标表现尚佳。其中，毛利率62.38%，同比增9.42%，净利率10.42%，同比 ...